Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Wearable devices offer exciting opportunities to longitudinally detect and track multi-modal stress and symptoms of disease in an objective and unobtrusive way.

Image shows silhouette of the top half a human body with the heart and brain highlighted.

The potential and emerging opportunities involving digital technology, stress and disease are highlighted in the article: Unlocking stress and forecasting its consequences with digital technology, which was published in the Nature Partner Journal, Digital Medicine, July 2019.

The availability and capabilities of digital devices have exploded in recent years. Smart phones, watches, rings, vests, scales, patches and even eyeglasses can produce different types of physiological data reflecting measures of the autonomic nervous stress system and objective digital biomarkers relating to activity patterns, daily routines, cognition, speech patterns, eye movements, and social activity.

The big data from these connected devices holds huge promise in discerning processes leading to disease. One of the major underpinnings of disease is stress, yet little progress in uncovering how it produces end stage illnesses such as acute episodes of major depression, flares in irritable bowel disease and symptoms or cardiac events has been made. 

 

Exposure to stress and individual reactions to stress are complex, fluid and dynamic. Until recently, we have had little means to measure, and discern the complexity associated with individual stress responses, and how these responses forecast disease.Sarah Goodday, Postdoctoral Researcher, Department of Psychiatry, University of Oxford.

 

Machine learning and artificial intelligence (AI) will be needed to translate the large volumes of data coming from digital devices and to decipher the complex inter and intra individual variation in stress and how it forecasts end stage illness. With the help of AI these tools could return signs of stress and early warning signs to individuals, offering personalised health management systems. 

 

 

 

 

 

The clinimetric properties of most wearable technologies is unknown, as well as, their capabilities for detecting early symptoms and stress.
Authors of the paper.

The market for wearable devices continues to saturate, outlining the importance of focusing efforts on large scale feasibility studies across different patient populations. Once the feasibility of using these digital tools to detect and track stress is established, these approaches offer real potential for pathways towards individualised care.

 

To read the full paper.

 

NIHR OXFORD HEALTH BIOMEDICAL RESEARCH CENTRE NEWS

Please follow the link below to read the news on the NIHR BRC website.

Similar stories

Treating mental illness with electricity - new podcast

A new wave of treatments that stimulate the brain with electricity are showing promise on patients and in clinical trials.

Hours of gaming not negatively impacting wellbeing of most adolescents - new study

University of Oxford researchers found that although many school-age adolescents are spending considerable time gaming, it is not having a negative impact on their wellbeing.

Few mental health apps make it to real world, according to new Oxford University study

Despite enthusiasm for digital technology in addressing young people’s mental health, few effective apps have been successfully rolled out.

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients.

Dementia research - new trial with diabetes drug

An important new trial will test the effects of oral semaglutide on the build-up of a protein in the brain that characterises Alzheimer's disease.